Last reviewed · How we verify
NCT05348668
Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer
Phase 2 trial testing Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors in Non-Small Cell Lung Cancer in 78 participants. Completed in 1 May 2025.
1 March 2025
Quick facts
| Lead sponsor | Anhui Provincial Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 78 |
| Start date | 1 March 2022 |
| Primary completion | 1 March 2025 |
| Estimated completion | 1 May 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors — full drug profile →
Conditions studied
- Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →
Sponsor
Anhui Provincial Hospital
Who can join
Adults 18 to 75, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The combination of immune checkpoint inhibitors (ICI) and local ablative radiotherapy has been demonstrated to be able to increase the survival of patients with metastatic driven-genes negative non-small cell lung cancer. Various dose-fraction of radiotherapy could exert different effects on the immune system. Ablative-dose could induce immunogenic cell death through the activation of CD8+(Cluster of Differentiation) T cells. Low-dose could modulate immune microenvironment from immunosuppression to inflammatory anti-tumor phenotype. This trial is designed to validation the safety and primary efficacy of the combination of hybrid dose-fraction radiotherapy with ICI for metastatic driven-genes negative non-small cell lung cancer patients.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immunogenic cell death-based cancer vaccines: promising prospect in cancer therapy.
Wang J, Ma J, Xie F, Miao F, et al · · 2024 · cited 19× · PMID 38745666 · DOI 10.3389/fimmu.2024.1389173 -
Using triple radio-immunotherapy to overcome cancer immunotherapy resistance.
Zhang Z, Zhang X, Chen D. · · 2023 · cited 1× · PMID 37975213 · DOI 10.20892/j.issn.2095-3941.2023.0268
Verify or expand the search:
- PubMed search for NCT05348668
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
- NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
- NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
- NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
Other Anhui Provincial Hospital trials
Trials by the same sponsor.
- NCT07523464 — Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC · Phase 1 · not yet recruiting
- NCT07481656 — Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) · Phase 4 · not yet recruiting
- NCT07462676 — Simultaneous Vs Staged VPS and CP :A Multi-cnter RCT. · NA · not yet recruiting
- NCT07211048 — Anti CD19 Gene Therapy for B-cell Lymphoma · NA · recruiting
- NCT07279844 — An Open-label, Observational, Long-term Follow-up Study Evaluating the Safety and Efficacy of RGL-193 Putamen Injection · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05348668 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anhui Provincial Hospital
- Last refreshed: 7 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05348668.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing